INTRODUCTION
Renal cancer is the third most common urologic cancer. Small renal masses (SRMs), defined as those less than four cm in diameter, are an increasing subset 1 .The continued rise in use of imaging has led to the increase in incidentally detected SRMs 2 . However, while the resolution of cross-sectional imaging has steadily improved, it is still challenging to confidently differentiate benign versus malignant masses of this size 3 . Percutaneous renal mass biopsy has long been put forward as one means of obtaining diagnostic data for these masses 4 . However, there has been a history of indeterminate results with these so the practice has not been generally utilized. Hence, for many patients with SRMs, treatment decisions are still being made without a clear diagnosis of malignancy.
The overarching goal of treatment for SRMs is the preservation of functional outcomes while addressing the tumor. Chronic kidney disease (CKD) is an indicator of morbidity, end stage renal disease and even mortality 5 . A high prevalence of CKD has been documented in patients with localized SRMs, with some series suggesting a rate of 25% of patients having CKD III or greater 6 .
Hence, the nephron-sparing partial nephrectomy procedure has been recommended and is now considered the gold standard for management of these masses 7 , particularly since the publication of several series suggesting worsening CKD and, in some cases, the new development of CKD after radical nephrectomy as compared to partial nephrectomy 5 . While emerging data question whetherextirpative management causes persistent subsequent CKD 8 9 , there is nonetheless a concern that more aggressive management may have undesirable sequelae in certain patients.
Other treatment modalities have also been proven successful in some patients 10 . Thermal ablation has been particularly useful in older or infirm patients 11 . Cryoablation, a form of thermal ablation in which the target tumor and surrounding parenchymal margins are frozen to critically low temperatures, likely has lower major complication rates as compared to surgery 10 . However, the short term rates of treatment failure may be greater than those of surgical management 10 . A third treatment option is active surveillance (AS).
This was initially described as a means of management of patients with SRMs who were not surgical candidates due to comorbidities or age 12 . AS is increasingly becoming adopted by physicians as a treatment plan for more patients.
In recent years, all therapeutic options are increasingly being offered to patients by their physicians. Choosing can be an overwhelming experience for some individuals. The multidisciplinary Small Renal Mass Center (SRMC) of the Sidney Kimmel
Cancer Center at Thomas Jefferson University Hospital was developed based on a previous model for prostate cancer first developed at this institution 13 14 . The goal of this clinic is to provide patients with all appropriate options such that patients are able to decide on an appropriate plan for management.
METHODS

CLINIC FORMAT
This concept was a spin off from our successful Multidisciplinary GU Oncology clinic established at Thomas Jefferson University
Hospital in 1996 to provide a more focused attention on this group of patients 13 . The SRMC comprises physicians and support staff We investigated nephrometry score 15 and BMI which showed no statistically significant differences as compared by treatment modality choice. However, for those patients with available data, there was a slight trend towards increased partial nephrectomy versus cryoablation in patients with low nephrometry scores (Table 1) .
RESULTS
Between
Pathology reports were obtained for patients who underwent partial or radical nephrectomies as well as a subset of patients who underwent cryoablation. Specimens were obtained after surgical resection or as needle biopsies performed during the cryoablation procedure. Similar to previous reports 16 , the majority of these SRMs were renal cell carcinomas (55.6%) with 12.3% oncocytomas, 18.0% angiomyolipomas and 13.9% otherwise benign or insufficient for diagnosis.
DISCUSSION
The assumption that providers are more likely to recommend the treatment modality they perform to patients presenting for consultation has been shown in the arena of low risk prostate cancer 17 . Surgeon characteristics have similarly been shown to influence treatment modality in patients with SRMs 18 . Evaluation of multidisciplinary clinics for prostate cancer have shown that patients seen in these settings, after presumably being introduced to all appropriate treatment options, may be more likely to undergo active surveillance for low risk prostate cancer 19 . The multidisciplinary clinic setting provides an opportunity for patients to fully evaluate possible treatment modalities. This arrangement often allows for a more extensive consultation than is normally available at the typical urologist's office. That, in addition to the opportunity to ask questions of the various physicians in the same setting may aid patients in choosing the treatment plan best suited to them and their families.
The treatment decision should take into consideration all viable options for a given patient, using all tools available to make that decision. One promising preoperative aid is the RENAL nephrometry score 15 . This is a quantitative method for characterizing the potential degree of difficulty involved in definitive management of a SRM. Our data do not indicate a statistically significant association between the assignment of nephrometry scores and treatment choice. However, there is a slight trend towards the performance of partial nephrectomies in patients with low nephrometry scores. We now make a point of performing a renal mass biopsy on all patients undergoing percutaneous ablation of a SRM when possible, and also employ it in cases where it will affect management. Current standard of care for SRM does not require a precise tissue diagnosis prior to definitive treatment. However, given that approximately one quarter of renal masses have been reported to be benign at surgery 21 , the ability to obtain evidence of malignancy will likely become an absolute imperative with time. The regular use of percutaneous biopsy as a diagnostic tool may decrease the number of procedures undertaken for benign masses. This has long been avoided in the field due to concerns over possible complications such as biopsy tract seeding with cancer cells and post-biopsy bleeding. Early attempts resulted in low diagnostic yield, leading to the widespread practice by physicians of foregoing biopsies prior to treatment 22 . There is now a growing body of evidence suggesting better yields and allaying the concerns for seeding 22 . A recent study demonstrated a correlation of 92% of biopsy with final pathology 23 . Moreover, biopsy can be used to give an indication of the aggressiveness of a given tumor since grade can be determined 24 . Although there continues to be some level of false negatives and indeterminate findings 25 , the concurrent performance of needle core biopsies and fine needle aspirates may increase diagnostic precision 24 . Increased success may come with immunostaining, thus diminishing the level of uncertainty involved.
In addition to consideration
The goal of management is to avoid compromising cancer specific survival. The SRMC presents a unique opportunity for patients to undergo consultation in a setting that allows for the appropriate presentation of treatment outcomes. Patients evaluate each treatment modality with the urologic oncology and interventional radiology teams simultaneously. This format encourages more thorough discussion of all options, thus enabling a more informed patient choice. We have recently incorporated the use of nomograms in our discussions on possible patient outcomes. Although not demonstrated to be statistically significant in this work, it is possible that specific patient characteristics including comorbidities and anatomic restrictions may influence decision making with regard to treatment options by the patient as well as the SRMC team. An additional consideration is the finding in several seriesthat most SRMs grow quite slowly 26 with mean growth rates less than 0.4 cm each year. Hence, AS can be adopted as an initial management plan which does not preclude later definitive treatment. Indeed, an emerging body of retrospective studies is showing similar patient outcomes with active surveillance versus more definitive treatment 12 . One recent multi-institutional study has also demonstrated equivalent short term overall and cancer specific survival in patients assigned to an active surveillance arm as compared to those who underwent nephrectomy or thermal ablation 27 . While this study was not randomized, our data have encouraged us to consider evaluating a more robust role for AS in the management of patients with SRMs. Through theSRMC, patients can be easily followed for several years such that new treatment decisions can be made as information or patient circumstances change.
However, there must be unwavering dedication byboth the patient and the treatment team to ensure that the patient returns in a timely fashion for periodic evaluation. Our review revealed that twenty-four (17.8%) of the patients who initially chose active surveillance were lost to follow up. This underscores the need for the multidisciplinary team to put safeguards in place to ensure that patients continue to be evaluated as necessary.
It is intriguing to surmise that the SRMC will influence treatment patterns at this institution. More extensive experience with this clinical model will allow for an evaluation of whether the SRMC influences treatment modality choice by patients. Future work will focus on determining the effect this multidisciplinary model has on improving long-term overall outcomes as well. This initial study of the SRMC is limited by its retrospective design as well as the relatively small patient numbers. Almost 20% of patients (64) were lost to follow up. Many had decided on a program of active surveillance. Since this is a tertiary referral center, patient loss was often due to patients'return to their home urologists for routine follow up. Additionally, there were losses due to patient death from other comorbidities.
CONCLUSION
The SRMC provides a novel opportunity for patients to evaluate all treatment modalities in an attempt to encourage more informed patient decision making with regard to care. Our current data suggest that older patients underwent the less invasive treatment modalities of active surveillance and cryoablation while those with higher estimated glomerular filtration rate were less likely to choose cryoablation as compared to partial nephrectomy. A longer term investigation will be performed to evaluate patient satisfaction levels and clinical outcomes as compared to other published series.
